Phase 2 NSCLC (Non-small Cell Lung Cancer) trials recruiting now

All NSCLC (Non-small Cell Lung Cancer) trials, every phase

Other phases for NSCLC (Non-small Cell Lung Cancer)

Phase 2 NSCLC (Non-small Cell Lung Cancer) trials

• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
  NCT07189871 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
  NCT06616766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
  NCT05592626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
  NCT06682793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
  NCT07120698 · Phase: Phase 2 · Ages: 28 Years to 75 Years · Sex: All (male and female) · 2 locations
• Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
  NCT06939127 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
  NCT05751798 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy
  NCT06667167 · Phase: Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
  NCT07609121 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
  NCT07528274 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)
  NCT07354061 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
  NCT06863506 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%
  NCT07596121 · Phase: Phase 2 · Ages: 65 Years and older · Sex: All (male and female) · 1 location
• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
  NCT07742332 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations
• WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
  NCT07330050 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.